Strides Pharma Science Peer Comparison

Strides Pharma Science Ltd. exhibits moderate growth and profitability compared to its peers, but its high valuation metrics suggest it may be overvalued. While it maintains a relatively strong debt level, its overall performance is overshadowed by companies with stronger financial metrics and lower valuations, positioning Strides as a potential sector laggard in terms of growth and profitability.

• • Strides Pharma shows moderate revenue growth (YoY) at 9.83%, lower than several peers.
• • High PE ratio of 138.44 signals potential overvaluation compared to earnings.
• • EPS growth is positive, but not competitive against peers like Cipla and Dr. Reddy's.
• • Debt levels are manageable but not the lowest in the sector.

• • Cipla Ltd.: Highest EPS growth and strong profitability metrics.
• • Dr. Reddy's Laboratories Ltd.: Consistent growth with low valuation metrics and strong returns.
• • Mankind Pharma Ltd.: High revenue growth and solid profitability make it a standout.